Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
Retrieved on:
Tuesday, March 28, 2023
CONNECT, Patent, Journal, Anxiety, Civil service commission, Journal of Neurodevelopmental Disorders, Silicon Valley Bank, NDA, Canaccord Genuity, Sales management, Depression, Silicon, FXS, INSPIRE, Fragile X syndrome, European Commission, Neurodevelopmental disorder, Patient, Behavior, FMR1, Development of the nervous system, Syndrome, Asset purchase agreement, MAA, Research, FDA, DiGeorge syndrome, Press release, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LPC, American College, Food, Pharmaceutical industry, Dietary supplement, Cryptocurrency, Cannabidiol, Jean-François Zygel
DEVON, Pa., March 28, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided an overview of recent operational highlights and a pipeline update.
Key Points:
- Published data in the Journal of Neurodevelopmental Disorders describing the role of the endocannabinoid system and cannabidiol therapy in FXS.
- Research and development expenses were $5.5 million for the fourth quarter of 2022, including stock-based compensation of $0.5 million.
- General and administrative expenses were $3.2 million in the fourth quarter of 2022, including stock-based compensation expense of $0.5 million.
- Net loss for the fourth quarter of 2022 was $8.0 million, with basic and diluted loss per share of $(0.18).